Medvi, the AI-powered telehealth company, is fueled by ads from doctors who don't appear to exist

Medvi projects $1.8B in sales this year after reporting $401M in business and $65M in profit last year, driven by AI-built systems and heavy affiliate marketing. Business Insider and Meta ad-library checks found numerous ads and pages with apparent AI-generated or fake doctor profiles (5,000+ ads then ~2,800), triggering an FDA warning, requests for FTC investigation, and at least three lawsuits over alleged spam and deceptive marketing. The combination of rapid revenue growth and alleged deceptive affiliate practices creates material regulatory and litigation risk that could pressure telehealth peers and advertising channels.

Analysis

Many direct-to-consumer digital health models lean on third-party affiliate acquisition, which creates structural fragility: platform enforcement can remove the marginal channel that drove 20–50% of new patients in a matter of days, and that shock typically doubles-to-quadruples short-term CAC while converting cohorts generated through non-compliant tactics fall 20–40% in LTV. Expect immediate churn in growth curves and CAC inflation across smaller operators; public guidance revisions will cluster in the next 1–3 quarters as boards and lenders force reined-in marketing programs.

Regulators and platforms will pursue two levers: (1) supervisory rules and fines that increase fixed compliance costs for firms selling regulated treatments, and (2) elevated moderation investment by ad platforms that raises CPMs for health verticals by an estimated 10–30%. Those forces make capital intensity higher for early-stage entrants and compress margins for players that cannot internalize compliance (likely material for firms with thin gross margins within 6–18 months).

Second-order supply effects are underpriced: pharmacies, compounding vendors, and fulfillment partners will face tighter audits and onboarding KPIs, increasing unit fulfillment costs 5–15% and creating intermittent supply frictions that can amplify patient drop-off. The most likely medium-term outcome is consolidation — compliant firms with integrated distribution and audited channels will buy growth cheaply; expect M&A windows in 12–36 months where regulated acquirers pay premiums for clean cohorts.

Catalyst timeline: near-term (days–weeks) = platform takedowns and headline volatility; medium (3–12 months) = FTC/FDA inquiries, litigation, guidance updates and earnings hits; long (12–36 months) = industry repricing and consolidation. The tail risk is aggressive enforcement and class-action settlements that can wipe out equity value for highly levered, customer-acquisition-dependent names within 3–12 months; the reversal would require regulatory inaction or a durable, low-cost compliant acquisition channel emerging.

Key Decisions for Investors

• Pair trade (3–6 month horizon): Long META (ticker: META) vs short Teladoc (ticker: TDOC), equal dollar exposure. Rationale: ad spend consolidation and higher CPMs should favor the dominant ad platform that can monetize stricter health-ad controls (META); smaller telehealth pure-plays with high marketing-driven growth are most exposed to CAC shocks. Target relative return: +10–20% in favor of META; stop-loss at 12% adverse move on the pair.
• Event/options trade (3–6 month horizon): Buy NYT 6-month call spread (ticker: NYT) to capture asymmetric upside from increased subscriber engagement driven by investigative coverage and industry volatility. Pay small premium (<2–3% of notional); target 30–50% upside to the spread if subscriber cohorts/heavy-traffic articles accelerate ARPU. Breakeven: modest given low cost of spread; exit on subscriber beat or 50% of target gain.
• Protection/short basket (6–12 month horizon): Establish put protection on a bespoke telehealth basket (primary ticker: TDOC) sized to 3–5% of book — buy 3–6 month 10% OTM puts or short concentrated names with >30% revenue from paid digital acquisition. Rationale: hedges against regulatory/investigative downside and forced re-rating. Risk/reward: premium paid is insurance; expected payout in regulatory-adverse scenarios where multiple guidance cuts occur.